Tudor Investment Corp ET AL Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Tudor Investment Corp ET AL decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 76.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,671 shares of the biopharmaceutical company's stock after selling 28,016 shares during the period. Tudor Investment Corp ET AL's holdings in Xenon Pharmaceuticals were worth $340,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Quarry LP purchased a new stake in Xenon Pharmaceuticals in the 4th quarter valued at about $78,000. Blue Trust Inc. grew its holdings in shares of Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after purchasing an additional 1,414 shares during the last quarter. Avior Wealth Management LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $101,000. KBC Group NV raised its holdings in Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth $210,000. Hedge funds and other institutional investors own 95.45% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on XENE shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price for the company. William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Chardan Capital initiated coverage on Xenon Pharmaceuticals in a research report on Wednesday. They issued a "buy" rating and a $55.00 target price on the stock. StockNews.com lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, May 2nd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $56.60.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $35.13 on Friday. The company's fifty day moving average price is $34.59 and its two-hundred day moving average price is $38.33. The firm has a market capitalization of $2.69 billion, a PE ratio of -12.46 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05. Analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.